Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma

Lung Cancer

Volumn 70, Issue 1, 2010, Pages 43-50

  Gaafar, Rabab ^a   Bahnassy, Abeer ^b   Abdelsalam, Ibrahim ^a   Kamel, Mahmoud M ^c   Helal, Amani ^a   Abdel Hamid, Amany ^b   Eldin, Nelly Aly ^a   Mokhtar, Nadia ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Malignant pleural mesothelioma; Prognosis; Serum and tissue EGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; EGFR GENE; FEMALE; GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE AMPLIFICATION; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77956190650     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.01.002     Document Type: Article

References (30)

1. Peto J., Decarli A., La Vecchia C., et al. The European mesothelioma epidemic. Br J Cancer 1999, 79:666-672.
2. Edwards J., Swinson D., Jones J., Waller D., O'Byrne K. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006, 54:399-407.
3. Gaafar R., Aly Eldin N. Epidemic of mesothelioma in Egypt. Lung Cancer 2005, 49:17-20.
4. Edwards J., Abrams K., Leverment J., Spyt T., Waller D., O'Byrne K. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000, 55:731-735.
5. Ogino H., Yano S., Kakiuchi S., Yamada T., Ikuta K., Nakataki E., et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett 2008, 265(1):55-66.
6. Olayioye M., Neve R., Lane H., Hynes N. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
7. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
8. Yarden Y., Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
9. Arteaga C. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 2002, 7:31-39.
10. Zhang X., Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non small cell lung cancer. Int J Med Sci 2008, 5:209-217.
11. Sasaki H., Yukive H., Mizuno K., et al. Elevated serum epidermal growth factor receptor levels is correlated with lymph node metastasis in lung cancer. Int J Clin Oncol 2003, 8:79-82.
12. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
13. Okuda K., Sasaki H., Kawano O., Yukiue H., Yokoyama T., Yano M., et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008.
14. Garland L., Rankin C., Gandara D., Rivkin S., Scott K., Nagle R., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007, 25:2406-2413.
15. Destro A., Ceresoli G., Falleni M., Zucali P., Morenghi E., Bianchi P., et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006, 51:207-215.
16. Ambs K.E., Takahahi A., Herring F., et al. Epidermal growth factor receptor in adenocarcinoma of the kidney. Urol Res 1989, 17:251-254.
17. Choi J.H., Oh J.Y., Ruy S.K., et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 1997, 79:1879-1883.
18. Zekri A-R.N., Bahnassy A., Mohamed W.S., Hassan N.A., Abdel-Rahman M.A., Abou-El-Kasem F., et al. Evaluation of siamian virus as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma. Pathol Int 2007, 57:493-501.
19. IMIG: Please add it.
20. Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. 2007; 20(10):1028-1035.
21. Betta P.-G., Libener R., Orecchia S., Bottero G., Filiberti R., Paganuzzi M., et al. Serum hepatocyte growth factor (HGF), epidermal growth factor (EGF), and stem cell factor (SCF) in pleural malignant mesothelioma. Proc ASCO 2002, 21:444a.
22. Schneider J., Presek P., Braun A., Bauer P., Konietzko N., Wiesner B., et al. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer 1999, 80:1987-1994.
23. Govindan R., Ritter J., Suppiah R. EGFR and HER-2 overexpression in malignant mesothelioma. Proc Am Soc Clin Oncol 2001, 20:3106.
24. Garland L., Rankin C., Scott K., Nagle R., Lobell M., Gandara D., et al. Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma. Proc ASCO 2004, 22:3007.
25. Govindan R., Kratzke R., hernodon J., Neihans G., Vollmer R., Watson G., et al. Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304.
26. Watzka S., Setinek U., Huber M., Cantonati H., Lax F., Watson S., et al. Reactivity of integrin-linked kinase in human mesothelial cell proliferation. Interact Cardiovasc Thorac Surg 2008, 7:107-110.
27. O'Byrne K., Edwards J., Waller D. Clinicopathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 2004, 45S:S45-S48.
28. Dazzi H., Hasleton P., Thatcher N., Wilkes S., Swindell R., Chatterjee A. Malignant pleural mesothelioma and epidermal growth factor receptor. Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990, 61:924-926.
29. Janne P., Taffaro M., Salgia R., Johnson B. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002, 62:5242-5247.
30. Cole G., Alleva A., Reddy R., Maxhimer J., Zuo J., Schrump D., et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD 153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg 2005, 129:1010-1017.